Physician profile
Stephen A Small
NPI 1124065339
$654.59
in general payments reported to CMS, 2019-2025
13 companies · $151 in 2025
The $151 reported for 2025 was more than what 75% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.59 · 2020: $28.27 · 2021: $20.27 · 2022: $120 · 2023: $187 · 2024: $107 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $138.71 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.67 | 2023-2025 | Xifaxan |
| Gilead Sciences, INC. | $78.22 | 2022-2025 | Veklury |
| Csl Behring | $61.86 | 2019-2023 | Kcentra |
| Abbvie INC. | $44.47 | 2022-2024 | Dalvance |
| Stryker Corporation | $40.26 | 2025 | Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $37.21 | 2023 | Camzyos, Eliquis |
| Vertex Pharmaceuticals Incorporated | $29.31 | 2025 | |
| Allergan, INC. | $28.27 | 2020 | |
| Bioxcel Therapeutics, INC. | $22.89 | 2023 | Igalmi |
| Kowa Pharmaceuticals America, INC. | $22.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.45 | 2022 | |
| Grifols USA, LLC | $14.41 | 2025 | Hyperrab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.